Latest analysis of lecanemab’s effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference
Stockholm, July 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results of a detailed analysis of the Phase 3 Clarity AD study, presented at the Alzheimer's Association International Conference (AAIC) 2023, demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI®) treatment showed benefits on both amyloid-beta (Aβ) and tau pathology as well as other downstream biomarker changes. In addition, new data on subcutaneous (SC) formulation shows promising PK/PD data modeling on efficacy and safety, representing a potential new